Theorem Clinical Research

Drug Sponsors

Roche acquires Trophos to expand neuromuscular disease portfolio

Wednesday, January 21, 2015 01:00 PM

Roche has agreed to acquire Trophos, a privately held biotechnology company based in Marseille, France. The company has developed a proprietary cholesterol-oxime based chemistry platform. Trophos's mitochondrial targeted compounds enhance the function and survival of stressed cells by preventing mitochondrial permeability transition, a key determinant of cell death or survival.

More... »

Quest Diagnostics

20 life sciences, IT organizations invest in tranSMART Foundation

Thursday, January 15, 2015 12:55 PM

The tranSMART Foundation, a nonprofit organization headquartered in Wakefield, Mass., providing a global, open-source knowledge management platform for scientists to share pre-competitive translational research data, said 20 life sciences and technology organizations have made substantial commitments by joining its membership program.

More... »


Tekmira Pharmaceuticals, OnCore Biopharma to merge

Wednesday, January 14, 2015 12:42 PM

Tekmira Pharmaceuticals, based in Vancouver, a developer of RNA interference (RNAi) therapeutics, and OnCore Biopharma, a Doylestown, Pa.-based biopharmaceutical company dedicated to discovering, developing and commercializing an all-oral cure for patients suffering from chronic hepatitis B virus (HBV) infection, have agreed to merge to create a new global HBV company focused on developing a curative regimen for hepatitis B patients by combining multiple therapeutic approaches.

More... »

Regado Biosciences, Tobira Therapeutics to merge

Wednesday, January 14, 2015 12:34 PM

Regado Biosciences, a development stage biotechnology company based in Basking Ridge, N.J., and Tobira Therapeutics, a clinical-stage biopharmaceutical company in South San Francisco, have agreed to merge. Privately held Tobira will merge with a wholly-owned subsidiary of Regado in an all-stock transaction. The merger will create a company focused on the development of novel treatments for liver and inflammatory diseases.

More... »

Qiagen acquires Enzymatics’ Enzyme Solutions Unit

Tuesday, January 13, 2015 10:30 AM

Qiagen, a Netherlands-based holding company, has acquired the Enzyme Solutions Unit of Enzymatics, a developer, manufacturer and OEM supplier of enzymes essential to driving the adoption of Next-Generation Sequencing (NGS) and other genetic analysis technologies in life sciences research and clinical healthcare.

More... »

Biogen Idec to acquire Convergence Pharmaceuticals, expands neuropathic pain portfolio

Tuesday, January 13, 2015 09:30 AM

Biogen Idec has agreed to acquire U.K.-based Convergence Pharmaceuticals, a clinical-stage biopharmaceutical company with an innovative portfolio of ion channel-modulating product candidates for neuropathic pain. Biogen Idec plans to leverage Convergence’s experience in chronic pain research and clinical development to accelerate the growth of its pain portfolio.

More... »

Roche to acquire majority ownership of Foundation Medicine

Monday, January 12, 2015 02:44 PM

Foundation Medicine (FMI), based in Cambridge, Mass., and Roche will enter into a broad strategic collaboration to further advance Foundation Medicine's position in molecular information and genomic analysis while providing Roche a unique opportunity to optimize the identification and development of novel treatment options for cancer patients. Roche also will acquire majority ownership of Foundation Medicine.

More... »

Shire to acquire NPS Pharma for $5.2 billion

Monday, January 12, 2015 02:38 PM

Dublin, Ireland-based Shire and NPS Pharmaceuticals have entered into a merger agreement, under which Shire will acquire all outstanding shares of NPS Pharma for $46 per share in cash, for a total consideration of approximately $5.2 billion.

More... »

Evotec, Padlock Therapeutics extend collaboration

Monday, January 12, 2015 02:32 PM

Evotec, a Germany-based drug discovery alliance and development partnership company, and Padlock Therapeutics, a private, Cambridge, Mass.-based biotechnology company dedicated to creating new medicines to treat destructive autoimmune diseases, have successfully completed an initial goal in a program focused on developing inhibitors of protein-arginine deiminases (PADs) and have further extended the collaboration that was first signed in January 2014.

More... »

Aveo announces executive transition, corporate restructuring

Thursday, January 8, 2015 12:59 PM

Aveo Oncology, based in Cambridge, Mass., has appointed Michael P. Bailey as the company’s president, CEO and director, effective immediately. Aveo also said it will eliminate the company’s internal research function, as well as certain corporate support positions, to align corporate resources with the company’s future strategic plans, focusing on advancement of its pipeline in the clinical setting.

More... »

AiCure
CWWeekly

March 30

Icon, Carnegie Mellon partner to research ways to improve study patients' understanding of Informed Consent

Veeva launches OpenKey, partner program to unlock difficult access to, restrictions on customer reference data

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

March

Novo Nordisk, Takeda, Servier, Celgene among top sponsors
New gains seen from patient- and site-centric initiatives

Patient reported outcomes take center stage
FDA combining PROs, clinical outcomes in its approval decisions

Already a subscriber?
Log in to your digital subscription.

Purchase the March issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

February

Study grants market breaks $13 billion
Volume of clinical activity rising while growth in grant spending slows

Revisiting eClinical Technology Solutions Adoption
While use of established solutions grows, sponsors hesitate on newer tools

Already a subscriber?
Log in to your digital subscription.

Purchase the February issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs